Stereospecific oxidation of the (S)-enantiomer of RS-8359, a selective and reversible monoamine oxidase A (MAO-A) inhibitor, by aldehyde oxidase

Xenobiotica

Volumn 35, Issue 6, 2005, Pages 561-573

  Itoh, K ^a   Yamamura, M ^b   Muramatsu, S ^b   Hoshino, K ^a   Masubuchi, A ^a   Sasaki, T ^a   Tanaka, Y ^a  

^a TOHOKU PHARMACEUTICAL UNIVERSITY   (Japan)

^b DAIICHI SANKYO CO   (Japan)

Author keywords

Aldehyde oxidase (AO); Biotransformation; Enzyme purification; Monoamine oxidase A (MAO A) inhibitor; Stereoselectivity

Indexed keywords

4 (4 CYANOANILINO) 6,7 DIHYDRO 7 HYDROXY 5H CYCLOPENTA[D]PYRIMIDINE; ALDEHYDE OXIDASE; CHLORPROMAZINE; CINCHONA ALKALOID; MENADIONE;

ANIMAL TISSUE; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOSOLIC FRACTION; DRUG DISTRIBUTION; DRUG STRUCTURE; DRUG TRANSFORMATION; ENZYME ACTIVITY; ENZYME PURIFICATION; LIVER CYTOSOL; MALE; MOLECULAR WEIGHT; NONHUMAN; OXIDATION; RAT; STEREOCHEMISTRY; STEREOSPECIFICITY;

ALDEHYDE OXIDASE; ANIMALS; CINCHONA ALKALOIDS; CYTOSOL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; LIVER; MALE; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; NITRILES; OXIDATION-REDUCTION; PYRIMIDINES; QUININE; RATS; RATS, WISTAR; STEREOISOMERISM; TISSUE DISTRIBUTION;

CINCHONA;

EID: 24144483424     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/00498250500202106     Document Type: Article

References (26)

1. Beedham C. 1985. Molybdenum hydroxylase as drug-metabolizing enzymes. Drug Metabolism Reviews 16:119-156.
2. Beedham C. 1987. Molybdenum hydroxylases: Biological distribution and substrate-inhibitor specificity. Progress in Medical Chemistry 24:85-121.
3. Beedham C. 1997. The role of non-P450 enzymes in drug oxidation. Pharmacy World Science 19:255-263.
4. Beedham C. 2002. Molybdenum hydroxylases. In: Ioannides C, editor. Enzyme systems that metabolise drugs and other xenobiotics. London: Wiley. pp 147-187.
5. Beedham C, Al-Tayib Y, Smith JA. 1992. The role of guinea pig and rabbit hepatic aldehyde oxidase in the oxidative in vitro metabolism of cinchona alkaloids. Drug Metabolism and Disposition 20:889-895.
6. Caldwell J, Winter SM. 1988. The pharmacological and toxicological significance of the stereochemistry of drug disposition. Xenobiotica 18:59-70.
7. Drayer DE. 1986. Pharmacodynamic and pharmacokinetic differences between drug enantiomers in human: An overview. Clinical Pharmacology and Therapeutics 40:125-133.
8. Gutzwiller J, Uskokovic MR. 1973. Reinvestigation of the classical synthesis of cinchona alkaloids. II. The synthesis of quinine and its naturally occurring diastereomers from quinotoxine. Helvetica Chimica Acta 56:1494-1503.
9. Holmes RS. 1979. Genetics, ontogeny and testosterone inducibility of aldehyde oxidase isozymes in the mouse: Evidence of two genetic loci (Aox-1 and Aox-2) closely linked on Chromosome 1. Biochemical Genetics 17:517-527.
10. Iwata N, Tonohiro T, Kozuka M, Kumagae Y, Takasaki W, Tanaka Y. 1996, A novel selective and reversible MAO-A inhibitor, RS-8359: Its pharmacological properties and metabolism. International Academy for Biomedical Drug and Research 11:285-286.
11. Iwata N, Yokoyama T. 1987. RS-2232 and 8359, a new reversible and specific inhibitors of A form of MAO. Pharmacology and Toxicology 60(Suppl. 1):25P.
12. Jamali F, Mehvar R, Pasutto FM. 1989. Enantioselective aspects of drug action and disposition: Therapeutic pitfalls. Journal of Pharmaceutical Sciences 78:695-715.
13. Kaye B, Rance DJ, Waring L. 1985. Oxidative metabolism of carbazeran in vitro by liver cytosol of baboon and man. Xenobiotica 15:237-242.
14. Ohkubo K, Sakiyama S, Fujimura S. 1983. Purification and characterization of N′-methylnicotinamide oxidase I and II separated from rat liver. Archives of Biochemistry and Biophysics 221:534-542.
15. Plenker A, Puchler K, Volz HP. 1997. The effects of RS-8359 on cardiovascular function in healthy subjects and depressed patients. International Clinical Psychopharmacology 12:S25-S29.
16. Puchler K, Sasahara K, Plenker A, Nitanai T, Witte PU. 1997. The pharmacokinetic profile of RS-8359. International Clinical Psychopharmacology 12:S11-S16.
17. Rajagopalan KV. 1980. Xanthine oxidase and aldehyde oxidase. In: Jacoby WB, editor. Enzymatic basis of detoxification. London: Academic Press, pp. 295-309.
18. Rashidi MR, Smith JA, Clarke SE, Beedham C. 1997. In vitro oxidation of famciclovir and 6-deoxypenciclovir by aldehyde oxidase from human, guinea pig, rabbit and rat liver. Drug Metabolism and Disposition 25:806-813.
19. Stell JGP, Warne AJ, Lee-Woolley C. 1989. Purification of rabbit liver aldehyde oxidase by affinity chromatography on benzamidine sepharose 6B. Journal of Chromatography 475:363-372.
20. Takasaki W, Yamamura M, Nozaki A, Nitanai T, Sasahara K, Itoh K, Tanaka Y. 2005. Stereoselective pharmacokinetics of RS-8359, a selective and reversible MAO-A inhibitor, by species-dependent metabolizing enzymes. Chirality 17:135-141.
21. Takasaki W, Yamamura M, Shigehara E, Suzuki Y, Tonohiro T, Hara T, Tanaka Y. 1999. Stereoselective pharmacokinetics of RS-8359, a selective and reversible inhibitor of A-type monoamine oxidase, in rats, mice, dogs, and monkeys. Biological and Pharmaceutical Bulletin 22:498-503.
22. Testa B, Mayer JM. 1988. Stereoselective drug metabolism and its significance in drug research. Progress in Drug Research 32:249-303.
23. Tucker GT, Lennard MS. 1990. Enantiomer specific pharmacokinetics. Pharmacology and Therapeutics 45:309-329.
24. Wright RM, Clayton DK, Riley MG, McManaman JL, Repine JE. 1999. cDNA cloning, sequencing and characterization of male and female rat liver aldehyde oxidase (rAOX1)-differences in redox status may distinguish male and female forms of hepatic AOX. Journal of Biological Chemistry 274:3878-3886.
25. Yokoyama T, Karube T, Iwata N. 1989. Comparative studies of the effects of RS-8359 and safrazine on monoamine oxidase in vitro and in vivo in mouse brain. Journal of Pharmacy and Pharmacology 41:32-36.
26. Yoshihara S, Tatsumi K. 1986. Kinetic and inhibition studies on reduction of diphenylsulphoxide by guinea pig liver aldehyde oxidase. Archives of Biochemistry and Biophysics 249:8-14.